BLUEJETNSEBlue Jet Healthcare Limited· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 9 Jul, 2026 · 20:01 IST

Blue Jet Healthcare QIP closes; raises about Rs 800 crore at Rs 506 per share

Qip At DiscountFund Raising View source PDFExplain this filing

BLUEJET · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
+8.3%Reaction day
₹575.75
prior close
₹608.00
announcement price
After-mkt
timing
Nifty Smallcap 250market+1.4%+7.0% vs market
Pharmaceuticals peers, median of 167sector+0.4%+7.9% vs sector

On the reaction day the stock moved 7.0 pts more than Nifty Smallcap 250 and 7.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-1.3
10m
-1.4
15m
-1.9
30m
-1.3
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
+8.3+1.4+7.0+0.4+7.9
Next day
+5.4+1.7+3.7+0.7+4.7
2d
+5.1+0.6+4.6+0.4+4.7
3d
+4.4+1.2+3.1+0.6+3.8
4d
+2.1+1.3+0.8+0.4+1.7
5d
+1.2+0.7+0.5-0.7+1.9
1w
+2.4+1.3+1.1+0.2+2.2
15d
+8.6+0.2+8.3-2.0+10.6
1m
+2.8+2.6+0.2-0.7+3.6
2m
-0.1+3.1-3.3+2.4-2.5
3m
-10.1-0.6-9.5-1.5-8.6
UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 167Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Blue Jet Healthcare has closed its QIP on July 9, 2026, allotting 1.58 crore equity shares at Rs 506 each (face value Rs 2), raising about Rs 800 crore. The issue price carries a 4.83 percent discount of Rs 25.70 per share to the floor price of Rs 531.70. The Investment and Finance Committee approved the closure, allocation, and placement document at a meeting held the same day.

Likely market impact

QIP dilution of about 4 to 5 percent. Pricing below floor price may weigh on near-term sentiment, though capital raise supports growth plans.